![Yong Ben](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 428 639 $ al 31/07/2026
En la actualidad, Yong Ben ocupa el cargo de director médico del departamento de inmunología y oncología de BeiGene Ltd. El Dr. Ben se doctoró en la Universidad Médica Norman Bethune y obtuvo un MBA en la Universidad de California San Diego.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,06 % | 01/07/2026 | 44.576 ( 0,06 % ) | 360 620 $ | 31/07/2026 |
| 19/05/2026 | 7.583 ( 0,04 % ) | 68 020 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Director/Miembro de la Junta | 01/03/2023 |
Eight Roads Capital Advisors (CHINA)
 Eight Roads Capital Advisors (CHINA) Investment ManagersFinance Functions as an alternative investment manager | Inversor de Capital Privado | 01/08/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| BEIGENE LTD | Director Técnico/Científico/I+D | - |
| BIOATLA, INC. | Corporate Officer/Principal | 01/02/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Norman Bethune Medical University
 Norman Bethune Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioAtla, Inc.
 BioAtla, Inc. BiotechnologyHealth Technology Develops novel monoclonal antibody and protein therapeutic products | Health Technology |
Corbus Pharmaceuticals Holdings, Inc.
 Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
BeiGene Ltd.
 BeiGene Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Eight Roads Capital Advisors (CHINA)
Eight Roads Capital Advisors (CHINA) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
